The Relationship of Hematological Parameters with Metabolic Syndrome in Type 1 and Type 2 Psoriasis

Year 2022, Volume: 32 Issue: 2, 150 - 153, 29.04.2022

Munise Daye , Selami Aykut Temiz

https://doi.org/10.54005/geneltip.1029729

Abstract

Objective: Psoriasis is a chronic, inflammatory disease with a rate of 2% in the population, with periods of remission and exacerbation. Psoriasis has been accepted as an independent risk factor for cardiovascular diseases and is known to be closely related to metabolic syndrome. It is known that the mean platelet volume (MPV), the platelet distribution width (PDW), the red blood cell distribution width (RDW) levels are parameters predicting systemic inflammation. Studies have found that some of these parameters can be used to predict metabolic syndrome in patients with psoriasis. In the literature, there is no study showing the relationship between the frequency of metabolic syndrome (MS) and hematological parameters by evaluating type 1 and type 2 psoriasis separately.
Materials and Methods: A total of 186 participants were included in the study, 93 patients over 18 years of age with psoriasis diagnosed and 93 age and gender equivalent control groups, who applied to the dermatology clinic.
Results: While PDW was significantly different between psoriasis and control group, RDW was significantly different in the type 2 psoriasis group compared to the type 1 psoriasis group. Although MPV, RDW, and PDW were higher in the MS groups for both type 1 and type 2 psoriasis groups, and they did not create a statistically significant difference in any of them.
Conclusions: This study showed that the frequency of MS and related parameters were different between patients with type 1 and type 2 psoriasis, and we found that type 2 psoriasis was more associated with MS. In addition, we think that among the inflammatory parameters, especially RDW, may be an important marker for type 2 and type 1 psoriasis and comorbidities.

Keywords

Psoriasis, metabolic syndrome, hematological parameters

Tip 1 ve Tip 2 Psöriasiste Hematolojik Parametrelerin Metabolik Sendromla Olan İlişkisi

Abstract

Amaç: Psoriazis, popülasyonda %2 oranında görülen, remisyon ve alevlenme dönemleri ile seyreden kronik, inflamatuar bir hastalıktır. Sedef hastalığı, kardiyovasküler hastalıklar için bağımsız bir risk faktörü olarak kabul edilmiştir ve metabolik sendromla yakından ilişkili olduğu bilinmektedir. Ortalama trombosit hacmi (MPV), trombosit dağılım genişliği (PDW), eritrosit dağılım genişliği (RDW) düzeylerinin inflamasyonu öngören parametreler olduğu bilinmektedir. Çalışmalar, bu parametrelerin bazılarının sedef hastalığı olan hastalarda metabolik sendromu tahmin etmek için kullanılabileceğini saptamıştır. Literatürde tip 1 ve tip 2 psoriazisi ayrı ayrı değerlendirerek metabolik sendrom (MS) sıklığı ile hematolojik parametreler arasındaki ilişkiyi gösteren bir çalışma saptanmamıştır.
Gereç ve Yöntemler: Çalışmaya dermatoloji kliniğine başvuran 18 yaş üstü 93 psoriazis tanılı hasta ve 93 yaş ve cinsiyet eşdeğeri kontrol grubu olmak üzere toplam 186 katılımcı dahil edildi.
Bulgular: PDW psoriazis ve kontrol grubu arasında anlamlı olarak farklıyken, RDW tip 2 psoriazis grubu ile tip 1 psoriazis grubu arasında anlamlı derecede farklı saptandı. MPV, RDW ve PDW hem tip 1 hem de tip 2 psoriazis gruplarında MS gruplarında daha yüksek olmasına rağmen istatistiksel olarak anlamlı bir fark saptanmadı.
Sonuç: Bu çalışma, tip 1 ve tip 2 psoriazisli hastalarda MS sıklığının ve ilişkili parametrelerinin farklı olduğunu gösterdi ve tip 2 psoriazisin MS ile daha fazla birliktelik gösterdiği saptandı. Ayrıca inflamatuar parametrelerden özellikle RDW'nin tip 2 ve tip 1 psoriazis ve komorbiditeler için önemli bir belirteç olabileceği saptandı.

Keywords

Psöriazis, metabolik sendrom, hematolojik parametreler

References

• Referans1. Temiz SA, Özer İ, Ataseven A, Dursun R, Uyar M. The effect of smoking on the psoriasis: Is it related to nail involvement?. Dermatologic Therapy. 2020;33(6):e13960.
• Referans2. Delaporte E. Immune-mediated inflammatory diseases and psoriasis. Ann Dermatol Venereol 2008;135:269-74.
• Referans3. Daye M, Temiz SA, Isık B. The relationship between lichen planus and metabolic syndrome. J Cosmet Dermatol. 2020;00:1–5. https://doi.org/10.1111/ jocd.13905
• Referans4. Günaydin A, Aytimur D, Özdemir, F. Psoriasis ve metabolik sendrom/Psoriasis and metabolic syndrome. Turkderm 2014;48(2),95.
• Referans5. Dogan S, Atakan N. Red blood cell distribution width is a reliable marker of inflammation in plaque psoriasis. Acta dermatovenerologica Croatica, 2017;25(1),26-26.
• Referans6. Korkmaz S. Mean platelet volume and platelet distribution width levels in patients with mild psoriasis vulgaris with metabolic syndrome. Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii, 2018;35(4),367.
• Referans7. Gürer MA, Adışen E. Psoriasis, Genel Bilgiler, Epidemiyoloji. Archives of the Turkish Dermatology & Venerology/Turkderm, 2008;42.
• Referans8. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Archives of dermatological research 2007;298(7):321.
• Referans9. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. Dermatology 2008;216(2):152-155.
• Referans10. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. Journal of Investigative Dermatology 2012;132(3):556-562,
• Referans11. Ataseven A, Temiz SA, Eren G, Özer İ, Dursun R. Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics. Journal of Dermatological Treatment. 2020;1-6.
• Referans12. Öztürk ZA, Dag MS, Kuyumcu ME, Cam H, Yesil Y, Yilmaz N, et al. Could platelet indices be new biomarkers for inflammatory bowel diseases. Eur Rev Med Pharmacol Sci 2013;17(3), 334-41.
• Referans13. Cakal B, Akoz AG, Ustundag Y, Yalinkilic M, Ulker A, Ankarali H. Red cell distribution width for assessment of activity of inflammatory bowel disease. Digestive diseases and sciences 2009;54(4):842-847.
• Referans14. Ephrem G. Red blood cell distribution width should indeed be assessed with other inflammatory markers in daily clinical practice. Cardiology 2013;124(1):61-61.